Increased Risk of Breakthrough Infection among Cytomegalovirus Donor Positive/Recipient Negative Kidney Transplant Recipients Receiving Lower Dose Valganciclovir Prophylaxis

被引：0
|
作者：
Stevens, D. [1 ]
Trofe-Clark, J. [1 ,2 ]
Blumberg, E. [2 ]
Wilck, M. [2 ]
Weikert, B. [2 ]
Goral, S. [2 ]
Bleicher, M. [2 ]
Sawinski, D. [2 ]
Abt, P. [2 ]
Levine, M. [2 ]
Porrett, P. [2 ]
Bloom, R. [2 ]
机构：
[1] Hosp Univ Penn, Philadelphia, PA 19104 USA
[2] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA
来源：
AMERICAN JOURNAL OF TRANSPLANTATION | 2013年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：321 / 321
页数：1
相关论文
共 50 条
  • [21] Cytomegalovirus infection and allograft rejection among pediatric heart transplant recipients in the era of valganciclovir prophylaxis
    Das, Bibhuti B.
    Prusty, Bhupesh K.
    Niu, Jianli
    Sue, Paul K.
    PEDIATRIC TRANSPLANTATION, 2020, 24 (08)
  • [22] Preemptive anti-cytomegalovirus therapy in high-risk (donor-positive, recipient-negative cytomegalovirus serostatus) kidney transplant recipients
    Hasegawa, Jumpei
    Hatakeyama, Shuji
    Wakai, Sachiko
    Omoto, Kazuya
    Okumi, Masayoshi
    Tanabe, Kazunari
    Mieno, Makiko
    Shirakawa, Hiroki
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2017, 65 : 50 - 56
  • [23] Twice Weekly Valganciclovir for Cytomegalovirus Infection Prophylaxis in Kidney Transplant Recipients with Delayed Graft Function on Hemodialysis
    Mehta, S. A.
    Katz, A.
    Dieter, R.
    Jen, P.
    Siegfried, J.
    Papadopoulos, J.
    Lewis, T.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2020, 20 : 784 - 784
  • [24] Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
    Wong, Diana D.
    van Zuylen, Wendy J.
    Novos, Talia
    Stocker, Sophie
    Reuter, Stephanie E.
    Au, Jane
    Foster, Charles S. P.
    Day, Richard O.
    Horvath, Andrea R.
    Endre, Zoltan
    Rawlinson, William D.
    MICROBIOLOGY SPECTRUM, 2022, 10 (03):
  • [25] Standard-versus Low-Dose Valganciclovir for Cytomegalovirus Prophylaxis in Intermediate-Risk Kidney Transplant Recipients.
    Wilson, N.
    Sulejmani, N.
    Jantz, A.
    Patel, A.
    Summers, B.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 532 - 532
  • [26] PREEMPTIVE THERAPY VERSUS UNIVERSAL PROPHYLAXIS WITH VALGANCICLOVIR IN MINIMIZING THE RISK OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS
    Khan, Muhammad
    TRANSPLANT INTERNATIONAL, 2019, 32 : 295 - 295
  • [27] African American Race Is an Independent Risk Factor for Cytomegalovirus Infection in Renal Transplant Recipients on Low-Dose Valganciclovir Prophylaxis
    Patel, S.
    Kuten, S.
    Loucks-DeVos, J.
    Knight, R.
    Gaber, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [28] The Efficacy and Safety of 200 Days Valganciclovir Cytomegalovirus Prophylaxis in High-Risk Kidney Transplant Recipients
    Humar, A.
    Lebranchu, Y.
    Vincenti, F.
    Blumberg, E. A.
    Punch, J. D.
    Limaye, A. P.
    Abramowicz, D.
    Jardine, A. G.
    Voulgari, A. T.
    Ives, J.
    Hauser, I. A.
    Peeters, P.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2010, 10 (05) : 1228 - 1237
  • [29] Preemptive Therapy is Cost Effective When Compared to Prophylaxis in Cytomegalovirus Donor Positive - Recipient Negative Liver Transplant Recipients.
    Wagener, M. M.
    Winston, D. J.
    Razonable, R. R.
    Lyon, G. M., III
    Silveira, F. P.
    Limaye, A. P.
    Singh, N.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 : 461 - 461
  • [30] PREEMPTIVE THERAPY VERSUS UNIVERSAL PROPHYLAXIS WITH VALGANCICLOVIR IN MINIMIZING THE RISK OF CYTOMEGALOVIRUS DISEASE IN KIDNEY TRANSPLANT RECIPIENTS
    Khan, Muhammad Tassaduq
    SWISS MEDICAL WEEKLY, 2019, : 19S - 19S
12345